Skip to main content
. Author manuscript; available in PMC: 2015 Feb 2.
Published in final edited form as: Neurobiol Dis. 2008 Nov 5;33(2):193–206. doi: 10.1016/j.nbd.2008.10.007

Figure 5.

Figure 5

Cytoskeletal proteins in the hippocampus after infusion of Aβ oligomers and/or GSK3 inhibitor (a) MAP-2-ir in representative sections shows dendritic staining in the stratum radiatum (SR) in response to intracerebroventricular infusion of vehicle (Veh), GSK3 inhibitor (SB), Aβ, or Aβ+SB. Treatment effects on induction of aberrant curly dendrites (black arrows) and MAP-2-ir accumulation in soma (black arrowheads) are shown. The right panel is a high magnification of the adjacent panel's black-boxed area to demonstrate the treatment impact on dendritic blebbing (white arrowheads). (b) In the CA1, Tau-1 (non-phosphorylated tau epitope 191–225) staining is present in the non-pyramidal layers. Phospho-Tau (CP13, phosphorylated serTau) staining is induced in soma and dendrites in responses to some treatments. (c) In the CA3, treatment-dependent induction of Tau-1 (non-phosphorylated) and CP13 (phosphorylated) tau in neuritic processes (black arrows) and soma (arrowheads). (d) Image analysis of CP13-ir in CA1 and CA3, demonstrating increased CP13-ir in SB and Aβ infusion groups (p<0.0001). Data are expressed as mean±SEM, n=7–11 per group. Scale bar=100 µm.